Print

RISVAC02

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers

Trial Details:

I Completed
Spanish Superior Scientific Research Council June 01, 2008
MVA-B Gag, Pol, Nef B
MVA-B Viral Vector - Pox
Spain 30